CO214 Model Predictions for Lifetime Health Benefits of Mobocertinib and Current Treatment Options in Post-Platinum Patients with Locally Advanced or Metastatic NSCLC Harboring Egfr Exon 20 Insertion Mutation in China
Abstract
Authors
G.Y. Zuo Y. Wang Y. Gao Y.J. Zhang F.F. Zhu